Free Trial

IDEAYA Biosciences (IDYA) Stock Forecast & Price Target

$42.21
-0.69 (-1.61%)
(As of 07/24/2024 ET)

IDEAYA Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 14 Wall Street analysts who have issued ratings for IDEAYA Biosciences in the last 12 months, the stock has a consensus rating of "Buy." Out of the 14 analysts, 14 have given a buy rating for IDYA.

Consensus Price Target

$52.92
25.37% Upside
High Forecast$69.00
Average Forecast$52.92
Low Forecast$33.00

According to the 14 analysts' twelve-month price targets for IDEAYA Biosciences, the average price target is $52.92. The highest price target for IDYA is $69.00, while the lowest price target for IDYA is $33.00. The average price target represents a forecasted upside of 25.37% from the current price of $42.21.

TypeCurrent Forecast
7/25/23 to 7/24/24
1 Month Ago
6/25/23 to 6/24/24
3 Months Ago
4/26/23 to 4/25/24
1 Year Ago
7/25/22 to 7/25/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
14 Buy rating(s)
13 Buy rating(s)
12 Buy rating(s)
9 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$52.92$48.27$46.60$29.40
Forecasted Upside25.37% Upside31.95% Upside32.15% Upside73.16% Upside
Get IDEAYA Biosciences Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IDYA and its competitors with MarketBeat's FREE daily newsletter.

IDYA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IDYA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IDEAYA Biosciences Stock vs. The Competition

TypeIDEAYA BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside25.13% Upside2,994.90% Upside10.36% Upside
News Sentiment RatingPositive News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/16/2024Wedbush
3 of 5 stars
 Reiterated RatingOutperform$56.00 ➝ $54.00+26.61%
7/12/2024JPMorgan Chase & Co.
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$65.00 ➝ $69.00+71.39%
7/11/2024Royal Bank of Canada
4 of 5 stars
 Boost TargetOutperform ➝ Outperform$53.00 ➝ $61.00+49.80%
7/9/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$55.00 ➝ $62.00+57.00%
7/8/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$53.00 ➝ $60.00+48.51%
7/8/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$63.00 ➝ $63.00+55.94%
7/8/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Suvannavejh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$50.00+45.94%
5/13/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$53.00 ➝ $46.00+11.81%
3/21/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$40.00 ➝ $60.00+31.72%
2/23/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/22/2024Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Chiang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
11/8/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$48.00 ➝ $44.00+42.53%
8/8/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$33.00+53.27%
8/8/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$33.00+53.27%
3/23/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$26.00+87.59%
11/18/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$18.00 ➝ $24.00+32.09%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:14 PM ET.

IDYA Forecast - Frequently Asked Questions

What is IDEAYA Biosciences' forecast for 2024?

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for IDEAYA Biosciences is $52.92, with a high forecast of $69.00 and a low forecast of $33.00.

Should I buy or sell IDEAYA Biosciences stock right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last twelve months. There are currently 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IDYA shares.

Does IDEAYA Biosciences's stock price have much upside?

According to analysts, IDEAYA Biosciences's stock has a predicted upside of 44.71% based on their 12-month stock forecasts.

What analysts cover IDEAYA Biosciences?

IDEAYA Biosciences has been rated by research analysts at BTIG Research, JPMorgan Chase & Co., Mizuho, Oppenheimer, Royal Bank of Canada, Stifel Nicolaus, The Goldman Sachs Group, and Wedbush in the past 90 days.

Do Wall Street analysts like IDEAYA Biosciences more than its competitors?

Analysts like IDEAYA Biosciences more than other "medical" companies. The consensus rating for IDEAYA Biosciences is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how IDYA compares to other companies.


This page (NASDAQ:IDYA) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners